Trexquant Investment’s Avidity Biosciences RNAM Stock Holding History

Trexquant Investment’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-76,495	Closed	-$2.22M	–	1830
2024 Q4	$2.22M	Buy	76,495 +60,685	+384%	+$2.54M	0.03%	824
2024 Q3	$726K	Sell	15,810 -23,724	-60%	-$1.03M	0.01%	1154
2024 Q2	$1.61M	Buy	+39,534	New	+$1.13M	0.02%	824
2024 Q1	–	Sell	-69,874	Closed	-$632K	–	1732
2023 Q4	$632K	Sell	69,874 -90,719	-56%	-$606K	0.01%	984
2023 Q3	$1.02M	Buy	160,593 +25,109	+19%	+$216K	0.03%	739
2023 Q2	$1.5M	Buy	135,484 +110,711	+447%	+$1.39M	0.04%	603
2023 Q1	$380K	Sell	24,773 -55,430	-69%	-$1.22M	0.01%	1101
2022 Q4	$1.78M	Buy	+80,203	New	+$1.2M	0.05%	449
2021 Q1	–	Sell	-13,370	Closed	-$341K	–	1413
2020 Q4	$341K	Buy	+13,370	New	+$390K	0.04%	621

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's RNAM Position: Q1 2025 in Review

Trexquant Investment sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 76,495 shares — an estimated $2.22M sold.

Trexquant Investment first reported a position in RNAM in Q4 2020 and held it in 9 quarters. The position peaked at $2.22M in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

Trexquant Investment reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
Trexquant Investment sold 76,495 Avidity Biosciences shares in Q1 2025, an estimated $2.22M.
Trexquant Investment first reported a position in Avidity Biosciences in Q4 2020 and held it in 9 quarters.
Trexquant Investment's Avidity Biosciences position peaked at $2.22M in Q4 2024.
220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Trexquant Investment's 13F filing for Q1 2025, filed 14 May 2025.